Annals of the Rheumatic Diseases
@ARD_BMJ
Followers
11,909
Following
238
Media
1,962
Statuses
5,433
Annals of the Rheumatic Diseases ( #1 research journal in Rheumatology). High quality, peer reviewed research.
Joined April 2010
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Rafah
• 1094549 Tweets
GW最終日
• 507186 Tweets
NUNEW 3RDMV IS OUT
• 401962 Tweets
井上尚弥
• 264607 Tweets
#CDTVライブライブ
• 263467 Tweets
Inoue
• 156732 Tweets
シェリン
• 116641 Tweets
陸奥一蓮
• 84859 Tweets
ボクシング
• 67133 Tweets
マリカ杯
• 65631 Tweets
大千秋楽
• 52282 Tweets
サプライズ
• 47193 Tweets
モンスター
• 37343 Tweets
BINGLING SACRIFICES FOR LOVE
• 33490 Tweets
井上ダウン
• 33083 Tweets
ジェシー
• 26515 Tweets
GW終了
• 25394 Tweets
井上選手
• 24131 Tweets
逆転3ラン
• 23215 Tweets
ハマスタ
• 21778 Tweets
筒香のホームラン
• 20283 Tweets
#アンメット
• 19737 Tweets
#GWを写真4枚で振り返る
• 14834 Tweets
#何かオモシロいコトないの
• 13094 Tweets
Białoruś
• 12630 Tweets
筒香選手
• 12400 Tweets
Last Seen Profiles
Pinned Tweet
Quiz time 🔠 Image in
#rheumatology
6⃣4⃣ year-old woman
👉
#hemianopsia
👀
#headache
🤕for 2 weeks
➡️Past dx:
#retroperitonealfibrosis
, remission in the past 2 yrs
🧪Slightly elevated CRP
🧠Mass-like lesion
👇See
#MRI
image &
#histology
in 🧵
WHAT'S THE MOST LIKELY DIAGNOSIS❓
Behcet's disease
8
Primary Angiitis of CNS
17
IgG4-related disease
182
Parasitic abscess
3
1
18
31
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
🔴 HCQ for all 5 mg/kg/day
🔴 GC as ‘bridging therapy’ or maintenance ≤ 5 mg/day
🔴 Prompt initiation of immunosuppressive and/or biological agents
@eular_org
👉
4
262
526
🚨 # 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis
1️⃣sensitivity 93%
2️⃣specificity 94%
0
144
309
2023 SLE Recommendations
🔹Lower GC dose (5 mg instead of 7.5)
🔹 Early use of biologics for corticosparing
🔹 Cyclophosphamide if life-threatening
🔹 MMF: new in hemato manif
🔹Lupus nephritis: VCL vs BEL???
🔹Maintain trt for 3 years then taper, except HCQ
#EULAR2023
NZ
1
115
207
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
▶️ Lupus proliferative Nephritis
🔴 Low-dose IV cyclophosphamide or MMF + glucocorticoids
🔴 Combination with belimumab or calcineurin inhib. should be considered.
👉
0
82
206
🤩All you want to know about
#JAKinhibitors
is in this
#review
❗
⛳
#efficacy
🛡️
#safety
🎯
#selectivity
🔢 1^/2^
#generation
👉 new paradigm for the treatment of
#inflammatorydiseases
#RA
#PsA
#SpA
#psoriasis
#IBD
#AD
🔗
@DanielAletaha
@MichaelBonell10
0
79
162
Treatment algorithms for the treatment of Behcet’s disease according to organ involvement (Part 1)
Pr. Gulen Hatemi
#EULAR2023
NZ
2
85
141
🚨 # 2022 ACR/EULAR classification criteria for Rheumatology classification criteria for microscopic polyangiitis
1️⃣sensitivity 91%
2️⃣specificity 94%
0
69
132
🚨 # 2022 ACR/EULAR classification criteria for Eosinophilic Granulomatosis with Polyangiitis
1️⃣ sensitivity 85%
2️⃣ specificity 99%
0
68
127
Check out our latest editorial revisiting the latest evidence on
#glucocorticoid
treatment in
#rheumatic
diseases:
▶️ mechanisms of action
▶️ adverse events (including cardiovascular and infection)
▶️ clinical studies
▶️ benefit/harm risk
▶️ tapering
🔗
0
59
126
❗ EULAR recommendations for
#cardiovascular
risk management in
#rheumatic
and musculoskeletal diseases, including systemic
#lupus
erythematosus and
#antiphospholipid
syndrome
0
57
121
Systemic literature review shows
👍 efficacy and safety of
#TNFi
and
#IL17i
in axial
#spondyloarthritis
🤥
#IL23i
failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety.
See details here 👉
0
50
115
Do not use direct oral anticoagulants to prevent
#thromboembolic
events in
#antiphospholipid
syndrome!⛔ It is associated with 69% increased risk of thromboembolic events compared with vitamin K antagonists according to this meta-analysis
4
71
115
🆕 Outstanding review on
#SLE
#pathogenesis
🦋 by Prof Mary Crow
@HSSProfEd
Critical mediators:
▶️type I
#interferon
🧪
▶️
#autoantibodies
targeting
#nucleicacids
& proteins🧬
🔥Genetic risk ➕triggers➡️ immune activation & autoantibody production
💊novel
#targetedtreatments
3
41
111
2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis
2
94
112
2023 PsA Recommendations
🔹Focus on safety
🔹Systemic GC removed
🔹NSAIDS limited place as monotherapy
🔹1. cs-DMARDS: MTX LEF SSZ
🔹2. b-DMARDs in no particular order
🔹3. JAKi
🔹4. Apremilast for mild cases
🔹Use EMMs to guide treatment
Pr Laure Gossec
@LGossec
#EULAR2023
NZ
2
53
105
🆕 The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease💎
🔢 If score>56 points ➡️ classify as
#CPPD
with 99.2%
#sensitivity
and 92.5%
#specificity
(validation cohort)
🔗
@A_Latourte
@FranciscaSivera
@Tuhina_Neogi
0
57
105
EULAR/PRES recos for sJIA & AOSD
🔹sJIA = AOSD l
👉 Unique name: Still’s disease
🔹Start IL1i or IL6i as soon as diagnosis made
🔹MAS ⚠️
🔹Emerging issue: lung disease
👉Screening (HRCT if suspicion)
#EULAR2023
Pr B Fautrel & F deBenedetti
Key slides 👇🏼
NZ
0
62
105
CAR T cells for treating autoimmune diseases
🔺 A state-of-the-art review
👉
1
49
100
🌟
@eular_org
2023 update on PsA management is out. Something we have all been eagerly waiting for 😱
These reco´s offer 7 OAP&11 recommendations for effective treatment strategies. A must-read 📚to navigate the latest in PsA care 🛳️ 💊🎯
🔗
0
39
98
🔺Initial treatment options for ILD associated with SARDs vs progression of ILD
❌No GCs in SSc
❗MMF as a first option
🔺Rapidly-progressive ILD for MDA5 patients
1
31
97
Check out the 2022 update of the
@eular_org
recommendations for the management of ANCA-associated vasculitis
✅ 4 principles, 17 recommendations
▶️ diagnosis (biopsy)
▶️ treatment (remission induction, glucocorticoid tapering, remission maintenance, use of immunosuppressants)
0
47
95
New
@eular_org
guidelines for imaging in managing crystal-induced arthropathies (CiAs) 🌟
With insights from an international team, these recommendations guide diagnosis, monitoring, and treatment across gout, CPPD, and more 🎯.
Dive into the manuscript:
1
54
91
Clinical course of
#COVID19
in a French case series of 17 patients with
#lupus
treated with
#hydroxychloroquine
Despite long-term treatment
#hydroxychloroquine
within the therapeutic range, it did not prevent
#COVID19
9
46
90
🚨New case series from 🇫🇷🚨
In patients with
#sj
ögren syndrome resistant to
#rituximab
(anti-RTX abs), the type II anti CD20 antibody
#obinutuzumab
led to a response in 50 % of cases and may be a therapeutic option in refractory cases.
🔗
2
40
82
Which biologic agent is associated with the highest risk of severe Covid-19? New French data including 1116 patients confirmed
#Rituximab
with an OR of 7.7 as more risky than other
#bDMARDs
. Implications for 💉
#vaccine
prioritization?
0
40
79
Do you know that the
@eular_org
School of Rheumatology offers free educational material?
Check out dedicated
#viewpoint
:
And access the material here:
0
31
76
The
#EULAR2020
is starting tomorrow and we are happy to present to you our fantastic guest tweeters for this event:
@javierrcarrio
@carmona_loreto
@Larhumato
@chriswincup
@FragoulisGeorge
0
20
72
New-onset ANCA-associated vasculitis without severe glomerulonephritis or alveolar haemorrhage: is 0.5 mg/kg/day prednisolone plus rituximab enough?🤔
This study in 140 Japanese patients say yes👍
👉 Same relapse frequencies
👉 SAEs were less frequent
0
28
72
Do not repeat
#ANA
testing: the gain is minimal!
#EULAR
Opening Plenary Abstract session
@carmona_loreto
1
62
72
RITAZAREM study: Rituximab, in conjunction with even relatively low doses of glucocorticoids, is highly effective at reinducing remission in patients with ANCA-associated vasculitis who have relapsed
2
45
71
Do you stop
#methotrexate
in your male patients who wish to conceive? No need to do so according to studies from the past few years: no increase in adverse pregnancy outcomes if paternal exposure. Prof. Monika Ostensen at
#EULAR2019
>LA
1
55
70
Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody
👫 56 patients NXP2+DM collected including 10 cases with GI involvements
⌛ Timely recognition and targeted therapy may turn out to be lifesaving
👉
0
23
68
💉Efficacy and safety of mRNA
#vaccines
for
#COVID19
in patients with
#rheumatic
patients with immunosuppressive therapies
✅considerable immunogenicity
✅side effects comparable to control individuals
✅no disease flares
🔗
@rheuma_doktorin
2
38
67
Fifty years after the discovery of the association of HLA-B27 with ankylosing spondylitis
⌛ Juergen Braun and Joachim Sieper summarizing half a century of
#spondyloatrhritis
history
👉
0
20
66
🆕 2023 update of the
@eular_org
recommendations for the use of
#imaging
in
#largevesselvasculitis
🔥
👉
@sofiaramiro82
@philipp_j_bosch
@cristinadbponte
@Sarah_L_Mackie
@Ertugrul_cagri
@jmolinacollada
@profbdasgupta
@annamolto
@ChristianDejaco
0
39
66
🔡
#Rheumatology
Quiz 🧐
43-year-old 🚺
🤒 fever
💥 low back pain
🕳️ skin ulcerations
⬆️⬆️ CRP
☢️ CT scans:
#erosions
on sacroiliac joints
🔍 Colonoscopy: active
#colitis
✂️ Skin biopsy: neutrophilic infiltrate,
#abscess
formation and
#necrosis
🔮 Post your guess! 👇
8
12
64
#secukinumab
at a dose of 150 and 300 mg per month is safe and effective for the long-term treatment of patients with
#Beh
çet’s syndrome with a mucosal and articular phenotype refractory to previous treatments
1
33
65
🚨new
#EULAR
recommendations for the diagnosis and management of type I interferonopathies🚨overarching principles:
1️⃣early morbidity and ↗️ mortality
2️⃣genetic dx required 🧬
3️⃣Rx aims at ↘️inflammation and ↗️QoL
4️⃣long-term care by multidisciplinary team
0
34
63
Is
#methrotexate
related to men fertility? Check out the results of the iFAME-MTX study:
▶️ MTX pre- and post-exposure does not affect semen parameters
▶️ no differences vs controls
▶️ MTX only marginally accumulated in spermatozoa
🔗
@DrReumatologo
1
49
64
🎯 A novel
#biomarker
for
#SystemicSclerosis
: anti-protein arginine methyltransferase 5 (PRMT5) antibody
👫 prediction of
#skin
&
#lung
involvement.
🐁 immunisation with recombinant protein PRMT5 induced SSc-like manifestations
🔗
0
39
69
Do you take care of
#SLE
patients on
#biologics
? 🦋
All you wanted to know about
#vaccinations
💉but never dared to ask for is here in this review! 👇
🔴 pneumococcus
⚪ influenza
⚫ SARS-CoV-2
🔵 varicella zoster
⭕ tetanus
🔘 other non-live 💉
👉
0
35
64
2023 EULAR recos for imaging in large vessel vasculitis
GCA
🔹 Early imaging, high expertise
🔹1. US of temporal AND axillary arteries
🔹2. MRI, FDG-PET
TAK
🔹1. MRI
🔹2. FDG-PET, CT or US
⚠️Conventional radiography NOT recommended
Dr Christian Dejaco
#EULAR2023
NZ
0
20
61
👉Pits and tips in myositis
🔹JAK inhibitors for calcinosis ?
🔹PCSK9 inhibitors are useful for anti-HMGCR associated autoimmune necrotizing myopathy
🔹PLEX + RTX useful for severe refractory myopathy
CS
1
28
62
Novel autoinflammatory disease with an ALPK1 gain-of-function mutation:
▶️ R etinal dystrophy
▶️ O ptic nerve oedema
▶️ S plenomegaly
▶️ A nhidrosis
▶️ H eadache
0
42
60
📣 Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’! 👋
🔄 Shift reflects early disease detection via MRI.
👥
@official_ASAS
endorses new nomenclature.
🆕 ASDAS acronym update 'Axial Spondyloarthritis Disease Activity Score'
1
28
61
Kawasaki-like disease following
#COVID
-19 (Kawa-COVID-19) in 16 paediatric patients
-age >5 years and ferritinaemia >1400 µg/L poor prognostic factors
-Severe disease (need for ICU) due to myocarditis in almost half
-Consider aggressive treatment promptly
2
37
61
🆕 The French Vasculitis Study Group Relapse Score (FRS) 📏 for
#ANCAvasculitis
3️⃣ factors at diagnosis of
#GPA
or
#MPA
predict a higher risk of relapse:
▶️ PR3-ANCA
▶️ age ≤75 years
▶️ EGFR ≥30 mL/min/1.73 m²
👉 Link:
@TerrierBen
1
31
61
Interested in novel therapeutic approaches in
#lupus
?
Check out our latest views article on novel agents:
#belimumab
#anifrolumab
#voclosporin
#obinutuzumab
🔗
1
26
60
Special release: New
#ACR
/
@eular_org
#SLE
#classification
criteria published today in ARD
-->
Want to know about it? Follow us on twitter to stay tuned for an interview with Prof. Martin Aringer
0
40
58
Upadacitinib therapy in refractory inflammatory myositis:
a case series of 10 patients
Does it work?
👉
0
24
55
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
2
39
56
New research 🔬: colchicine use 💊 is safe & effective for crystal-induced arthritis flares in patients with severe chronic kidney disease🚫🔥.
Low doses were well-tolerated & effective in 83% of cases, offering hope where few alternatives exist 🛡️🩺☝️
0
15
57
❓ What do you think the best choice for
#maintenance
treatment in
#ANCAvasculitis
is?🔥
Remission rate in 277 pts over 84 months 🇫🇷
18-month fixed RTX > AZA
& >18-month tailored RTX
🔗
@Delestreflo
@Maxime_Samson21
@OrphaLung
@NJourde
@TerrierBen
0
28
57
What are the drugs that work in interstitial lung disease in RMDs?
➕
Bonus: Oxford Evidence Levels
#EULAR2023
NZ
3
20
55
📍Low-dose daily colchicine in CPPD is recommended as an additional benefit to:
⬇️reduce CV risk in adults with known atherosclerotic disease or multiple traditional CV risk factors.
❓should Colchicine be considered for cases with no / one CV risk factors? 👇🏼
#ACR23
AM
0
15
55
Should all patients with
#polymyalgia
rheumatics be screened for
#giantcellarteriitis
with vascular
#ultrasound
? A recent viewpoint summarizes the evidence:
📊prevalence of subclinical GCA may be as high as 25%
3
30
55
New and important study on
#glucocorticoids
and bone health in inflammatory rheumatic diseases. doses <5 mg/d together with low disease activity seem to have a low risk for
#osteoporosis
0
37
52
✔️ The Outcome Measures in Rheumatology (
#OMERACT
) Ultrasound Working Group generated a consensus-driven ultrasound dactylitis score for psoriatic
#arthritis
😍🖐️ =GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS)👍 see the details here 👉
1
16
54
Anti-SMN autoantibodies in MCTD associated with a severe systemic sclerosis phenotype
🔺 Retrospective MCTD cohort
🔺 66 patients
▶️ 59% Anti-SMN aAbs +
▶️ Associated w severe SSc phenotype: myositis, myocarditis & lower GI involvement
👉
0
26
54
Comparison of
#cardiovascular
risk in >100 000
#RA
patients betweem those exposed to
#tofacitinib
and to
#TNFi
💓
#population
-based no increased risk in those with tofacitinib
0
25
51
🔍 Unlock the future of PsA treatments! 🔑 Dive into the evidence behind the updated
@eular_org
2023 Recommendations 🔬 Your roadmap to optimized PsA management and improved life quality awaits 💪📖
Explore now! 🔭👇
🔗
0
27
52
🧐 Have you ever wondered where
#enthesis
in the hand fingers are? 🖐️
🔍 preliminary GLobal
@OMERACT
Ultrasound DActylitis Score (GLOUDAS) in
#psoriaticarthritis
💀 32 entheses identified in cadaveric fingers
🔡 12 selected for inclusion in GLOUDAS
🔗
9
11
53
Is it
#VEXAS
or idiopathic relapsing
#polychondritis
? VEXAS-RP is characterised by:
✔️high prevalence of male sex
✔️fever
✔️skin lesions
✔️ocular, pulmonar and heart involvement
✔️ older age
✔️ MDS association
✔️ higher risk of death
0
22
52
💥💡The latest from the German RABBIT register🇩🇪 📰 shows: NO increased risk of MACE associated with JAK inhibitors 💊❤️⛑️ compared to other RA meds, even in high-risk patients! 💉🚫
But different unadjusted IRs for individual JAKi
#RWD
#JAK_Selectivity
?
@DRFZ_Berlin
1
18
51
🗞️ What's in the current Annals' issue?
Shift in perspective: autoimmunity protecting against
#rheumatoid
arthritis
🔎 What if the ACPAs are protective in pre-RA instead of pathogenic?
👉 Check out the interesting insights in
#antibodies
0
18
51
🆕 Severe, treatment-refractory diffuse cutaneous
#SSc
treated with CD19-CAR T cells.
A 60-year-old 👨 :
▶️ diffuse myocardial & lung
#fibrosis
▶️ pulmonary
#hypertension
▶️ carpal
#arthritis
▶️ anti-RNA pol III
See response to
#CARTcell
👇
👉
0
23
51
How to predict thrombosis in antiphospholipid syndrome?
▶️ three prediction scores were prospectively evaluated: global APS score, Padua, Caprini score
▶️ all models performed suboptimal
▶️ venous and arterial thrombosis should be predicted separately
🔗
0
29
52
🆕Potential treatment for
#SjogrenSyndrome
🤩
❌ Inhibition of JAK-STAT pathway able to correct:
👅 salivary gland
#inflammation
💥 interferon-driven
#immuneactivation
➡️ Ongoing
#RCT
with
#tofacitinib
🔗
@SarthakGuptaMD
@blakewarner0
@sarfarazhasni
2
22
50
Genotype analysis define new illnesses such as VEXAS.
”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner.
Science enthusiasm at 3S038. Autoinflammatory Diseases.
@petercgrayson
#ACR20
<TK
0
11
50
New
@eular_org
/
@ACRheum
points to consider at the early stages of
#diagnosis
and management of suspected
#haemophagocytic
#lymphohistiocytosis
/macrophage activation syndrome
- 6 overarching statements
- 24 specific Ptc
#diagnose
#manage
and
#monitor
0
35
50
Viral screening before immunosuppressive therapy:
🔸 HBV infection (HBsAg, anti-HBc, anti-HBsAb)
🔸Pre-emptive therapy in all HBsAg + and HBV-DNA + patients & monitoring in all isolated anti-HBc
🔸 Rituximab warrants therapy regardless of HBV DNA
@LCalabreseDO
#ACR23
@ACRheum
0
17
50
🤔 What do you think is the short-term
#effectiveness
&
#safety
of
#RTX
vs
#CYC
for life-threatening
#ANCAvasculitis
?🔥
🗾 Real-world nationwide data from Japan 🇯🇵
◼️ mortality RTX = CYC
🔹 fungal infection risk RTX < CYC
🔴 haemodialysis RTX > CYC
🔗
0
16
49
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
1
28
48
🔬 Fascinating Trial in AAV
💉 Comparing RTX dosing strategies: B cell repopulation vs. ANCA level rise.
📊 Results: Fewer relapses with B cell strategy.
👩⚕️ Safety similar, though higher COVID-19 SAEs in B cell group
🎯 A step towards precision medicine
1
21
49
The long awaited
@eular_org
points to consider on pathophysiology and use of immunomodulatory therapies in
#COVID19
are just published.
Also watch out for the accompanying
#SLR
- soon to be out!
0
21
49
👆 Autoantibodies can serve as markers for classification, diagnosis, prognosis and disease activity 👉 Here is an overview of recent studies published in ARD that have significantly expanded our knowledge of autoantibodies in
#RMD
.
0
22
47
🔭 Intriguing viewpoint by
@nikolasruffer
&
@KruscheMartin
on
#VEXASsyndrome
: A diagnostic puzzle 🎨
〰️ “Normals” teach us rules; “outliers” teach us laws 〰️
➡️ More
#inflammatorydiseases
caused by
#somaticmutations
will explain yet unsolved puzzles
0
28
48
Are you familiar with the concept of pre-RA ? These are people with anti-CCP marker and inflammation on MRI but no pain. A randomized trial abatacept vs placebo shows less MRI signs and more importantly less clinical RA. Rech et al. Plenary session
#ACR21
> FB
2
17
48
Update of the
@eular_org
#recommendations
for
#vaccination
in adult patients with
#autoimmune
#inflammatory
#rheumatic
diseases just published. See the overarching priniciples at first glance attached!
FULTTEXT:
0
37
48
#EULAR2021
is starting tomorrow! 😲
We are looking forward reporting for you!
Meet our team of fabulous guest tweeters for this conference:
📣
@LatikaGupta_
@carmona_loreto
@KragstrupTW
@lauraandreoli80
@Larhumato
0
8
47
👉Interesting research on HCQ drug monitoring intervention
🔺Optimal levels 750-1200 ng/ml > 71% lower odds of active SLE
CS
1
15
47
🚨Our latest research on
#axial
#spondyloarthritis
is out. Check out the latest updates on:
▶️epidemiology
▶️pathogenesis
▶️imaging
▶️diagnosis
▶️management
▶️research agenda
🔗
1
22
46
#Lupus
flare risk was higher after
#hydroxychloroquine
taper/discontinuation versus hydroxychloroquine maintenance: data from the SLICC cohort
0
22
44
Immunophenotyping of 46 immune cell types in blood:
👉 4 clusters:
🔹 SLE and MCTD
🔹 AAV, IIM, GCA
🔹 controls, SjS, SSc, IgG4RD
🔹AS, psoriasis, RA
👉 in
#RA
patients: subclusters define disease activity and treatment responses
Read all results here
0
23
45
📃Fresh of press:
#Colchizine
in a randomized controlled trial targeting hospitalised patients with
#COVID19
.
Reducing the length of oxygen therapy and hospitalisation
1
23
45